NasdaqGM exchange. Sector: Healthcare. Industry: Biotechnology. Location United States, Pittsburgh.

Krystal Biotech, Inc. [KRYSUnited States

69.96USD0.13 (+0.19%)

• At close Thu Oct 06 2022

1,909,807,360 USD
MARKET CAP
.
PE
0.871
BETA (5y)
-1.712
EPS

profit

602%

for 5 years

profit

203%

for 3 years

profit

34%

for 2 years

profit

0%

for 1 year

profit

19%

for this year

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

We are doing some work on the site. Please come back later.

Krystal Biotech, Inc.
https://www.krystalbio.com
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.